

June 29, 2010



## **DispersinB(R) Technology for Development of Disease Resistant Biotech Crops**

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 06/29/10 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the invention of biotech plants producing DispersinB® antibiofilm enzyme. This provides a proof of concept for developing bacterial disease resistant agricultural crops of economic importance.

"Just like humans and animals, plants must constantly fight against bacterial infections, which account for billions of dollars of losses in crop yields and quality annually. The genetic engineering of plants will help defend against these pathogens and have a large impact on agricultural productivity. In 2009, 14 million farmers in 25 countries grew biotech crops on 134 million hectares generating \$10.5 billion in seed/licensing revenues", stated Gord Froehlich, President and Chief Executive Officer of Kane Biotech.

The prevention of agricultural crop diseases such as 'soft rot' and 'bacterial wilt' is made possible by preventing the biofilm formation of bacterial pathogens *Erwinia carotovora* and *Ralstonia solanacearum*, respectively. DispersinB®-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. Additionally, this biotech plant can also be used as a bioreactor for commercial scale production of DispersinB® enzyme; an alternative to the fermentation process currently used to produce DispersinB®.

"DispersinB®-expressing plants produced substantial amounts of the biologically active enzyme and showed inhibitory as well as dispersal activity against *Staphylococcus epidermidis* biofilm", stated Dr. Jeffrey B. Kaplan, Associate Professor, Department of Oral Microbiology, at the University of Medicine and Dentistry of New Jersey. "Furthermore, these plants showed resistance to *E. carotovora*, which causes 'soft rot' disease in staple food crops such as potatoes and cassava, and they should also be resistant to 'bacterial wilt' disease caused by *R. solanacearum*".

"This new discovery has applications in preventing major bacterial diseases in crops that involve biofilms which can be up to 1000 times more resistant to antimicrobials than their planktonic counterparts and has the potential to substantially reduce the agricultural losses in crops such as potatoes, tomatoes and cassava worldwide", stated Mr. Froehlich.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms

form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

#### Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts:

Kane Biotech Inc.

Gord Froehlich

President & Chief Executive Officer

204-477-7592

204-453-1314 (FAX)

[ir@kanebiotech.com](mailto:ir@kanebiotech.com)

[www.kanebiotech.com](http://www.kanebiotech.com)